These tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders shall be integrated into clinical practice by Apollo's subsidiary, Sapien Biosciences in partnership with Strand Life Sciences, it said in a statement yesterday.
"These tests will help doctors diagnose disease more precisely, identify the optimal treatment and monitor disease and treatment course for better outcomes," it said.
Genomic testing involves analysis of patient genomes genes and sequences of DNA/RNA. The analysis helps create better prognostic tools for improved disease screening and prevention strategies. The patient benefits from optimised clinical care, personalisation of treatment and monitoring of outcomes, it was noted.